HOME >> MEDICINE >> NEWS
Dynavax Demonstrates Ability Of Immunostimulatory DNA Sequences To Inhibit Symptoms Of Allergic Asthma In Animal Model

BERKELEY, CA (December 15, 1998): Injections of proprietary immunostimulatory DNA sequences (ISS-DNA), under development by Dynavax Technologies Corporation, can alter the nature of the immune response in allergic asthma, while also inhibiting the symptoms of that disease, the company announced. Dynavax scientists and their collaborators published research in the December 15 issue of the Journal of Immunology showing that a single systemic or mucosal (intranasal or intratracheal) administration of ISS-DNA in an animal model of allergic asthma inhibited disease symptoms as effectively as systemic corticosteroids administered daily for seven days. Moreover, unlike the corticosteroids, ISS-DNA injections were able to redirect the immune response away from the strong Th2 response associated with allergic inflammation toward a non-allergic Th1 response.

"This study demonstrates in vivo, for the first time, that ISS-DNA can be used as a drug to both inhibit and modify allergic disease," said Dino Dina, M.D., president and chief executive officer of Dynavax. "In fact, our lead ISS-DNA molecule has proven active in every animal species that Dynavax scientists and their collaborators have tested to date, including primates. Based on their research, we believe that ISS-DNA therapy may provide a totally novel, highly effective therapy for chronic allergic pulmonary inflammation."

The Journal of Immunology study was authored by Dynavax founder, Eyal Raz, M.D. and David Broide, M.B. Ch.B. of the Department of Medicine, University of California, San Diego; and their collaborators Helen Tighe, Ph.D., Minh-Duc Nguyen, and Siamak Malek at Dynavax; Tim Gifford and John Van Uden at the University of California, San Diego; and Jurgen Schwarze, M.D. and Erwin W. Gelfand, M.D. at the Department of Pediatrics, National Jewish Medical and Research Center in Denver, CO.

In the study, the researchers used a mouse model of allergen-induced airway hyperresponsiveness to investi
'"/>

Contact: Joan Kureczka
jkureczka@aol.com
415-821-2413
Kureczka/Martin Associates
15-Dec-1998


Page: 1 2 3

Related medicine news :

1. Clinical Trial Demonstrates Experimental Growth Factor Increases Eligibility For Autologous Stem Cell Transplantation
2. New Report Demonstrates That Following Guidelines Improves Clinical Practices, Reduces Liability Costs
3. Study Demonstrates The Benefits Of Mammography In Women Under 50
4. Study Demonstrates Safety & Effectiveness Of Asthma Drug
5. Inhibitors prevent aggresome formation associated with some forms of ALS
6. Inhibiting Growth Of New Blood Vessels Reduces Heart Disease Plaque In Mice
7. Acetylcholinesterase Inhibitors May Be Another Piece In Alzheimers Jigsaw
8. New Protease Inhibitor Could Thwart AIDS Resistance To Current Drugs
9. Hunter College Biologist Marie Filbin Identifies Mechanism That Blocks All Inhibitors Of Nerve Regeneration; Breakthrough Reported In Neuron Magazine
10. Antabuse May Inhibit Fatal Reaction To Anesthetic
11. HIV Patients Treated With Protease Inhibitors Are More Likely To Engage In Risky Sex, Emory Researchers Report

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/19/2019)... NEW ORLEANS (PRWEB) , ... June 19, 2019 , ... ... using mothers in the United States, has filed class action lawsuits in 34 ... Named as defendants in the class actions are an array of pharmaceutical manufacturers, distributors ...
(Date:6/18/2019)... ... , ... EMulate Therapeutics, Inc. , a clinical-stage therapeutic ... has received notice that the US Food and Drug Administration (FDA) accepted for ... Pediatric system. The FDA granted the Humanitarian Use Device (HUD) designation for ...
(Date:6/16/2019)... NEWPORT BEACH, Calif. (PRWEB) , ... June 14, ... ... Data Protection / Cyber Security solutions, today announced it has received the ... showcasing the award winning DLP that Works Platform along with the latest additions ...
(Date:6/14/2019)... ... 2019 , ... Docs is proud to present the following recently reviewed and approved providers for May 2019. , FL ... , BREAST SURGERY, Dr. Debbie Berlin , CARDIOLOGY, ... Dr. Christopher J. Pastore , Dr. Yamilet Tirado , DERMATOLOGY, ...
(Date:6/13/2019)... ... June 13, 2019 , ... ... Second Test (BL30SEC) has been accepted by the 2019 National Conference of Interstate ... N requirements. , The Charm BL30SEC test was validated by third party ...
Breaking Medicine News(10 mins):
(Date:6/13/2019)... ... June 13, 2019 , ... Recent lawsuits, including Hyatt ... back problem, underscore the responsibility of employers to provide reasonable accommodations to their ... are reasonable and which are not - from requests by hearing-impaired and disabled ...
(Date:6/13/2019)... ATLANTA (PRWEB) , ... June 13, 2019 , ... ... is celebrating 10 years of educating medical professionals and the public about non-invasive ... PBM this fall in Orlando, Florida to help commemorate the milestone. ...
(Date:6/13/2019)... ... June 13, 2019 , ... HMP, a leading healthcare education and events company, ... “Top 25 Fastest-Growing Shows in Net Square Footage” by Trade Show News Network (TSNN). ... growth over that period. Winners will be honored during the 2019 TSNN Awards, taking ...
Breaking Medicine Technology:
Cached News: